HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

edelfosine

RN given refers to parent cpd

Also Known As:

1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine; 1-O-octadecyl-2-methyl-3-phosphatidylcholine; 1-octadecyl-2-methoxy-sn-glycero-3-phosphorylcholine; 1-octadecyl-2-methoxyglycero-3-phosphorylcholine; 1-octadecyl-2-methyl-sn-glycero-3-phosphocholine; 1-octadecyl-2-methylglycero-3-phosphocholine; 2-methoxy-PAF; ET-18-O-methyl; ET-18-OCH(3); ET-18-OCH3; ET18-OMe; edelfosine, (+-)-isomer; edelfosine, (R)-isomer; edelfosine, (S)-isomer

Networked: 140 relevant articles (11 outcomes, 14 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Mollinedo, Faustino: 29 articles (11/2015 - 10/2002)
2.	Gajate, Consuelo: 19 articles (11/2015 - 10/2002)
3.	Verheij, Marcel: 7 articles (05/2014 - 02/2003)
4.	Mollinedo, F: 6 articles (05/2012 - 03/2000)
5.	Estella-Hermoso de Mendoza, Ander: 5 articles (10/2013 - 02/2009)
6.	Gajate, C: 5 articles (05/2012 - 03/2000)
7.	Klarenbeek, Jeffrey B: 5 articles (11/2011 - 01/2007)
8.	van Blitterswijk, Wim J: 5 articles (11/2011 - 02/2003)
9.	Hac-Wydro, Katarzyna: 4 articles (05/2014 - 03/2010)
10.	Acuña, A Ulises: 4 articles (07/2013 - 08/2004)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2009 - "In the present study, a novel ultra high performance liquid chromatography-tandem mass spectrometry method (UHPLC-MS/MS) was developed to quantify edelfosine concentrations in biological matrices (plasma, tissues or tumor) and in lipid nanoparticles, and compared with a conventional high performance liquid chromatography-mass spectrometry method (HPLC-MS). " 02/01/2009 - "In vivo biodistribution studies revealed that accumulation of edelfosine in the tumor of a MCL-bearing mouse animal model was considerably higher (P < 0.01) than in the other organs analyzed. " 11/01/1995 - "Our previous studies indicate that the selective inhibition of tumor cell growth by ET-18-OCH3 may be due to altered signal transduction mechanisms, including the inhibition of PKC. " 11/01/2015 - "Edelfosine induces apoptosis in hematologic cancer cells and activated T-lymphocytes. " 06/10/2015 - "Edelfosine showed a preferential action on ES tumor cells as compared to non-transformed osteoblasts, and appeared to be well suited for combination therapy regimens. "
2.	Leukemia 01/01/1993 - "Twenty-nine patients with acute leukemia in second or subsequent remission or early relapse or in first remission, either with a history of treated extramedullary relapse, or requiring more than one induction program to achieve remission, underwent ablative therapy followed by infusion of autologous marrow which had been purged by a 4-hour exposure to edelfosine prior to cryopreservation. " 07/01/1998 - "Here we study two human leukemia cell lines (HL-60 and K562) that have different sensitivities to edelfosine; HL-60 cells are more sensitive than K562 cells. " 02/05/1998 - "In this study, we confirmed a previous finding that 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (methyl-PAF) expresses higher antineoplastic activity against the promyelocytic leukemia cell line HL-60, than against the erythroleukemic cell line K562, and intended to clarify the reason for this. " 08/04/2014 - "Edelfosine lipid nanoparticles overcome multidrug resistance in K-562 leukemia cells by a caspase-independent mechanism." 11/01/2008 - "In liposomal form, edelfosine remains apoptogenic for a variety of leukemia cell lines, while its haemolytic effect is abolished. "
3.	Breast Neoplasms (Breast Cancer) 10/01/2013 - "Efficacy of edelfosine lipid nanoparticles in breast cancer cells." 11/01/2002 - "When used under conditions that reduce CD34-positive human bone marrow cells only 5.1-fold, and murine and human granulocyte/macrophage progenitors 6.8- and 3-fold, respectively, combination purging with MC540-PDT and Edelfosine depletes murine (Mm5MT) and human (MDA-MB-435S) breast cancer cells >17,000- and >125,000-fold, respectively. " 11/01/2002 - "We report here that if MC540-PDT is followed by a 1-h incubation with the alkyl-lysophospholipid, Edelfosine (ET-18-OCH(3)), the depletion of murine and human breast cancer cells is greatly enhanced whereas the recovery of normal hematopoietic stem and progenitor cells is only minimally degraded. " 05/03/1996 - "Possible interference with mechanisms involving intracellular pH (pHi) regulation was examined by measuring the effect of ET-18-OCH3 on the activity of the Na+/H+ exchanger in the breast cancer-derived cell line MCF-7. " 11/01/2002 - "These data suggest that combination purging with MC540-PDT and Edelfosine may offer a simple, safe and effective method for the ex vivo purging of autologous stem cell grafts from breast cancer patients."
4.	Fibrosarcoma 11/01/1987 - "ET-18-OCH3 influx and equilibrium binding of ET-18-OCH3 were decreased in a fibrosarcoma cell variant (MethA) selected for ET-18-OCH3 resistance. " 01/01/1985 - "We investigated the effect of ET-18-OCH3 on invasion of MO4 mouse fibrosarcoma cells and on cellular activities possibly related to invasion in vitro. " 10/01/1995 - "It is more effective than edelfosine in increasing survivors and reducing tumor volume in the oral mouse Meth A fibrosarcoma model. " 09/01/1990 - "One of the new compounds, SDZ 62-406, was selected for in vivo studies and showed oral and i.v. activity in the mouse MethA fibrosarcoma model in the same range as ET-18-OCH3. " 01/20/1995 - "5-[4'-(Piperidinomethyl)phenyl]-2,3-dihydroimidazo[2,1- a]isoquinoline (SDZ 62-434, 53) was more effective on a milligram per kilogram basis than the clinical cytostatic agent edelfosine (1) in increasing survivors and decreasing tumor volume in the oral mouse Meth A fibrosarcoma assay. "
5.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/01/2014 - "Earlier studies on the animal model of MS, experimental autoimmune encephalomyelitis (EAE), have generated first evidence for the efficacy of edelfosine treatment. " 02/01/1992 - "The effect of one alkyllysophospholipid, ET-18-OCH3, on the course of experimental autoimmune encephalomyelitis was investigated. " 01/01/1991 - "Inhibition of chronic relapsing experimental allergic encephalomyelitis in the mouse by the alkyl-lysophospholipid ET-18-OCH3." 09/15/2014 - "We examined mechanisms of action of edelfosine on immune functions in experimental autoimmune encephalomyelitis, a well-accepted animal model for multiple sclerosis. " 09/15/2014 - "Immunomodulatory effects of the ether phospholipid edelfosine in experimental autoimmune encephalomyelitis."

Related Drugs and Biologics

1.	miltefosine
2.	Liposomes (Liposome)
3.	gemcitabine
4.	Mitomycin (Mitomycin-C)
5.	Fluorouracil (Carac)
6.	Cisplatin (Platino)
7.	irinotecan (Camptosar)
8.	N,N,N',N'- tetrakis(2- pyridylmethyl)ethylenediamine
9.	trichostatin A (A 300)
10.	ruberythric acid (AlP)

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Drug Therapy (Chemotherapy)
3.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
4.	Heterologous Transplantation (Xenotransplantation)
5.	Oral Administration